Innoviva (INVA) Non-Current Deffered Revenue (2010 - 2017)
Innoviva's (INVA) quarterly Non-Current Deffered Revenue came in at $1.6 million in Q3 2017, down 36.3% YoY from $2.4 million in Q3 2016, and down 12.47% on a QoQ basis from $1.8 million in Q2 2017.
Analysis
Innoviva (INVA) Non-Current Deffered Revenue (2010 - 2017) Analysis & Trends
Innoviva (INVA) has 8 years of Non-Current Deffered Revenue data on file, last reported at $1.6 million in Q3 2017.
- Quarterly Non-Current Deffered Revenue fell 36.3% year-over-year to $1.6 million in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $1.6 million (down 36.3% YoY) and the FY2016 annual result came in at $2.2 million, down 28.56% from the prior year.
- Non-Current Deffered Revenue declined to $1.6 million in Q3 2017, from $1.8 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $5.7 million in Q1 2013 to a low of $13000.0 in Q2 2014.
- A 5-year average of $2.8 million and a median of $2.7 million in 2016 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2014 — Non-Current Deffered Revenue sank 99.72% — and 2016, when it surged 3133.71%.
- Tracing INVA's Non-Current Deffered Revenue over 5 years: stood at $5.5 million in 2013, then sank by 30.56% to $3.8 million in 2014, then slipped by 18.19% to $3.1 million in 2015, then decreased by 28.56% to $2.2 million in 2016, then declined by 29.95% to $1.6 million in 2017.
- The last three Non-Current Deffered Revenue figures came in at $1.6 million (Q3 2017), $1.8 million (Q2 2017), and $2.0 million (Q1 2017), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2017 | 1.55 Mn |
| Jun 30, 2017 | 1.77 Mn |
| Mar 31, 2017 | 1.99 Mn |
| Dec 31, 2016 | 2.21 Mn |
| Sep 30, 2016 | 2.44 Mn |
| Jun 30, 2016 | 2.66 Mn |
| Mar 31, 2016 | 2.88 Mn |
| Dec 31, 2015 | 3.10 Mn |
| Sep 30, 2015 | 3.32 Mn |
| Jun 30, 2015 | 3.54 Mn |
| Mar 31, 2015 | 3.76 Mn |
| Dec 31, 2014 | 3.79 Mn |
| Sep 30, 2014 | 4.06 Mn |
| Jun 30, 2014 | 4.33 Mn |
| Mar 31, 2014 | 5.25 Mn |
| Dec 31, 2013 | 5.46 Mn |
| Sep 30, 2013 | 5.15 Mn |
| Jun 30, 2013 | 5.75 Mn |
| Mar 31, 2013 | 5.67 Mn |
| Dec 31, 2012 | 6.01 Mn |